Benzinga | Oct 12, 2021 06:39AM EDT

RBC Capital Initiates Coverage On aTyr Pharma with Outperform Rating, Announces Price Target of $22

RBC Capital analyst Kennen MacKay initiates coverage on aTyr Pharma (NASDAQ:LIFE) with a Outperform rating and announces Price Target of $22.